Skip to content
World of Video Gaming – Lifestyle
Home
Sample Page
Author:
TORL Biotherapeutics LLC
TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
June 18, 2026
TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer and Evolves Leadership for Next Phase of Growth
May 7, 2026